.svg)
Strategy+ Credentials
Strategy+ is credited with over 100 deals and has facilitated over $250B in deal value. Our team is armed by the power of our global strategic partnerships.
“Working with Strategy+ at Pfizer is a masterclass in deal-making. I’d jump at the chance to work with them and highly recommend them to anyone looking for a top-tier deals expert.”
%201.svg)
“We worked with Strategy+ for 2 years on various M&A activity. Their capacity is seemingly endless, they are very sharp, organized and strategic in their approach.”
“I would like to recommend Strategy+ for their outstanding contribution in the deal space. They show a deep understanding of the financial markets and an impressive network of industry contacts.”
“We had the pleasure of working with Strategy+ at a Fortune 500 company. They handle complexity with remarkable skill and provide clean and actional insights in the world of deals. We highly recommend them for anyone seeking an expert to make a difference.”
“Strategy+ has a unique talent for taking complex ideas and turning them into clear strategies. They consistently offer invaluable insights that improve our M&A outcomes. I highly recommend them to any team looking for a smart, strategic partner.”
.svg)
.webp)
.webp)
%20(1).webp)
.webp)
.webp)
fortune global clients
.svg)
Retained by multiple Insurance companies to advise on various transactions resulting in a $6.7 Billion investment from Warren Buffett.
Capital Raise Due Diligence
$6.7 Billion
Retained by Pfizer (NYSE: PFE) to support on various Acquisition, Divestiture and Capital Raises over 10+ years.
Deal Origination Due Diligence Sign + Close
$200 Billion+
Generated and advised on $20 Billion+ in M&A transactions over 3+ years.
Due Diligence IPOs Sign + Close
$20 Billion+
Retained by Pfizer (NYSE: PFE) to advise on the largest pharma transaction in history, the $160 Billion merger of Pfizer (NYSE: PFE) with global pharmaceutical company Allergan plc (NYSE:AGN).
Deal Origination Due Diligence
$160 Billion
Raised $100 Million for ACI Worldwide (NASDAQ: ACIW) on the cash sale of its corporate online banking solutions to middle market private equity firm, One Equity Partners.
Capital Raise Due Diligence
$100 Million
Retained by TransUnion (NYSE: TRU) on The Acquisition Of Verisk Financial (NASDAQ: VRSK) for $1.2 Billion. Strategy+ negotiated savings of $700M against JP Morgan & McKinsey in the DD process.
Due Diligence
$1.2 Billion
Retained by Pfizer (NYSE: PFE) on the $12 Billion merger of UpJohn and Mylan into Viatris (NASDAQ: VTRS).
Deal Origination Due Diligence IPO
$12 Billion
Retained by Pfizer (NYSE: PFE) on the $810 Million Acquisition of Therachon Holding AG, a privately-held clinical-stage biotechnology company focused on rare disease.
Capital Raise Due Diligence
$810 Million
